Traditional Chinese medicine interventions targeting the gut–kidney axis in diabetic kidney disease: pharmacological evidence and translational challenges

Diabetic kidney disease (DKD) is a major cause of chronic kidney disease and kidney failure worldwide. The gut–kidney axis, encompassing gut microbial dysbiosis, altered microbial metabolites, intestinal barrier dysfunction, and systemic and intrarenal inflammation, has emerged as a potential contributor to DKD progression. Traditional Chinese medicine (TCM) formulas, single botanical drugs, botanical extracts and enriched fractions, and purified phytochemicals or their chemically modified derivatives have increasingly been investigated as modulators of this axis, although the underlying mechanisms remain incompletely understood. This narrative review summarizes current clinical and preclinical evidence concerning the effects of TCM interventions on the gut–kidney axis in DKD. Literature searches of PubMed and Web of Science from database inception to September 2026, supplemented by manual screening of relevant reference lists, informed this review. Available studies suggest that TCM interventions may improve renal phenotypes in association with restoration of intestinal barrier integrity, modulation of gut microbial composition, and regulation of metabolites such as short-chain fatty acids, indole derivatives, protein-bound uremic toxins, bile acids, and trimethylamine N-oxide. However, only a limited number of studies have used antibiotic-mediated microbiota depletion, fecal microbiota transplantation, or direct metabolite intervention to examine microbiota-related causality. Product characterization, dose justification, randomization, blinding, and analytical quality control also remain inconsistently reported, while clinical evidence is still limited. Overall, current findings suggest a potential contribution of the gut microbiota and its metabolites to the renoprotective effects of TCM. Future studies using chemically standardized preparations, pharmacologically relevant dosing, rigorous experimental controls, causal microbiome approaches, systematic safety assessment, and adequately powered clinical trials are needed.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-13
DOI
https://doi.org/10.3389/fphar.2026.1886105
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Traditional Chinese medicine interventions targeting the gut–kidney axis in diabetic kidney disease: pharmacological evidence and translational challenges

Wei Zhang, Yuanyuan Luo, Zhihai Feng, Suqin Shi
3 links
Frontiers in Pharmacology
Gut microbiota and health
article

Traditional Chinese medicine interventions targeting the gut–kidney axis in diabetic kidney disease: pharmacological evidence and translational challenges

Wei Zhang, Yuanyuan Luo, Zhihai Feng, Suqin Shi
article en

Abstract

Diabetic kidney disease (DKD) is a major cause of chronic kidney disease and kidney failure worldwide. The gut–kidney axis, encompassing gut microbial dysbiosis, altered microbial metabolites, intestinal barrier dysfunction, and systemic and intrarenal inflammation, has emerged as a potential contributor to DKD progression. Traditional Chinese medicine (TCM) formulas, single botanical drugs, botanical extracts and enriched fractions, and purified phytochemicals or their chemically modified derivatives have increasingly been investigated as modulators of this axis, although the underlying mechanisms remain incompletely understood. This narrative review summarizes current clinical and preclinical evidence concerning the effects of TCM interventions on the gut–kidney axis in DKD. Literature searches of PubMed and Web of Science from database inception to September 2026, supplemented by manual screening of relevant reference lists, informed this review. Available studies suggest that TCM interventions may improve renal phenotypes in association with restoration of intestinal barrier integrity, modulation of gut microbial composition, and regulation of metabolites such as short-chain fatty acids, indole derivatives, protein-bound uremic toxins, bile acids, and trimethylamine N-oxide. However, only a limited number of studies have used antibiotic-mediated microbiota depletion, fecal microbiota transplantation, or direct metabolite intervention to examine microbiota-related causality. Product characterization, dose justification, randomization, blinding, and analytical quality control also remain inconsistently reported, while clinical evidence is still limited. Overall, current findings suggest a potential contribution of the gut microbiota and its metabolites to the renoprotective effects of TCM. Future studies using chemically standardized preparations, pharmacologically relevant dosing, rigorous experimental controls, causal microbiome approaches, systematic safety assessment, and adequately powered clinical trials are needed.

Frontiers in PharmacologyVol. 17
Kunming University of Science and Technology (CN), Henan University of Traditional Chinese Medicine (CN), First People's Hospital of Yunnan Province (CN), First Affiliated Hospital of Henan University of Traditional Chinese Medicine (CN), First Affiliated Hospital of Henan University (CN)
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon